A5014576160- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Biomarkers in Disease Mechanisms
- Systemic Lupus Erythematosus Research
- Lipid metabolism and disorders
- Autoimmune and Inflammatory Disorders Research
- Inflammasome and immune disorders
- Selenium in Biological Systems
- Reproductive Biology and Fertility
- Sphingolipid Metabolism and Signaling
- Systemic Sclerosis and Related Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pregnancy and Medication Impact
- Vasculitis and related conditions
- Peroxisome Proliferator-Activated Receptors
- Proteoglycans and glycosaminoglycans research
- Sperm and Testicular Function
- Protease and Inhibitor Mechanisms
- Psoriasis: Treatment and Pathogenesis
- Reproductive biology and impacts on aquatic species
Vestre Viken Hospital Trust
2021-2022
Innlandet Hospital Trust
2016-2019
Kent Hospital
2016
Inflammatory arthritis (IA), including rheumatoid (RA), ankylosing spondylitis (AS) and psoriatic (PsA), leads to increased cardiovascular disease occurrence probably due atherosclerosis. One of the first stages in atherogenesis is endothelial dysfunction (ED). Therefore, we aimed compare function (EF) patients with IA, examine effects methotrexate (MTX) monotherapy antitumor necrosis factor (anti-TNF) treatment or without MTX comedication (anti-TNF ± MTX) on EF. From PSARA observational...
Pentraxin 3 is proposed to be a marker of inflammation and cardiovascular risk, but its role in inflammatory rheumatic diseases (IRDs) still uncertain. Therefore, we wanted examine if anti-rheumatic treatment reduced serum PTX3 (s-PTX3) levels IRDs, s-PTX3 were related other markers endothelial function (EF).We examined s-PTX3, EF established biomarkers 114 IRD patients from the PSARA study before after 6 weeks months with methotrexate (MTX) or anti-tumor necrosis factor alpha (anti-TNF)...
Background The complement system is involved in pathogenesis of cardiovascular disease, and might play a role accelerated atherogenesis spondylarthropathies (SpA). Hence, we examined activation SpA, its relationship to antirheumatic treatment, inflammatory markers. Methods From PSARA, prospective observational study, 51 SpA patients (31 psoriatic arthritis (PsA), 20 ankylosing spondylitis (AS)), starting tumor necrosis factor (TNF) inhibitor alone (n = 25), combined with methotrexate (MTX)...
The endothelial glycocalyx (EG) is essential for proper function of the endothelium and vascular integrity, but its role in premature atherogenesis rheumatoid arthritis (RA) has not been studied yet. EG impairment can play a pathogenesis disease, one characteristics shedding syndecan-1 from cells. Syndecan-1 mediated by matrix metalloproteinase-9 (MMP-9) counteracted tissue inhibitor metalloproteinases (TIMP)-1. Cardiovascular disease risk RA reversible modifying antirheumatic drugs...
Spondyloarthropathies (SpA) are associated with increased cardiovascular risk. Among possible mechanisms is the dysfunction of serum lipoproteins in regulating cell cholesterol homeostasis. Cholesterol efflux capacity (CEC)-the atheroprotective ability HDL (high density lipoproteins) to accept from macrophages-might predict disease independently HDL-cholesterol levels. We aimed at evaluating modifications CEC and atherogenic loading (CLC) psoriatic arthritis (PsA) ankylosing spondylitis (AS)...
Background Patients with autoimmune arthritis (AA) are at increased risk for impaired cardiac function and heart failure. This may be partly due to the effect of inflammation in function. The impact antirheumatic drugs on dysfunction AA remains controversial. Therefore, we aimed examine effects treatment serum N-terminal pro-brain natriuretic peptide (NT-proBNP) patients its relationship inflammatory markers. Methods We examined 115 (64 rheumatoid (RA), 31 psoriatic 20 ankylosis spondylitis)...
<h3>Background</h3> Patients with rheumatoid arthritis (RA) are predisposed to impaired cardiac function and heart failure (HF). While the pathophysiology has not been fully elucidated yet, inflammation is suspected play an important role. However, impact of disease-modifying antirheumatic drugs on dysfunction in RA remains controversial. Although anti-inflammatory might have protective effects, some them, i.e. tumour necrosis factor inhibitors (anti-TNF), also negatively influence function....
<h3>Background</h3> PTX3, an important component of the innate immune system,has been proposed as a useful biomarker inflammation and cardiovascular (CV) risk, but its role in inflammatory rheumatic diseases (IRDs) is still uncertain [1,2]. <h3>Objectives</h3> The aim this study was to examine if methotrexate (MTX) and/or anti-tumor necrosis factor treatment (anti-TNF) reduced serum PTX3 (s-PTX3) levels IRDs (RA, PsA AS), s-PTX3 were related other markers endothelial function (EF)....
<h3>Background</h3> Inflammatory rheumatic diseases (IRD) are associated with accelerated atherosclerosis, which progression is related to inflammation. One of the first stages in atherogenesis endothelial dysfunction (ED). <h3>Objectives</h3> We wanted examine effects methotrexate (MTX) and anti-tumor necrosis factor (TNF) treatment (with or without MTX co-medication) on function (EF) rheumatoid arthritis (RA), psoriatic (PsA) ankylosing spondylitis (AS). <h3>Methods</h3> From data registry...
<h3>Background</h3> Spondyloarthritis is associated to accelerated atherosclerosis, possibly due chronic inflammation and lipid metabolism disturbances. Circulating lipoprotein function may be more important than concentration. In particular, cholesterol efflux capacity (CEC) of high density lipoproteins (HDL) opposes foam cell formation correlates inversely with cardiovascular risk<sup>1</sup>. Instead, the low (LDL) load cells (CLC) favors atherosclerosis. CEC CLC altered independently...